Endocrinology

Current Trials & Studies
Study nameStudy TitleStudy TypeSponsorSponsor Type
Redefine 2"Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes" Clinical Trial (NCT05394519)Novo NordiskCommercial: Industry